Sadler et al. [120] reported a number of notable findings: (1) SCFA levels in the blood decreased after stroke; (2) artificial SCFA supplementation reduced the expression of CD68 in Iba-1+ microglia, as well as decreased the number of microglia activation, which reduced the inflammatory response in the brain group after stroke. This evidence concerns the gene CD68 and stroke disorder.